Figure 2.

(A) Primary treatment response analysis of oliceridine compared with placebo (treatment responders at 48 hours).

Notes: This primary endpoint analysis compared the percentage of treatment responders in each oliceridine regimen with the percentage of responders in the placebo regimen at 48 hours post-loading dose. (B) Treatment responders over the full treatment period. Responders were those who reached a ≥30% improvement in time-weighted SPID-48 from baseline while not receiving rescue pain medication, discontinuing study medication early, or reaching dosing limits. *P<0.0001 vs placebo (Hochberg adjusted).

Abbreviation: SPID, sum of pain intensity difference.